CO4700422A1 - Producto farmaceutico que comprende una cantidad sinergica de un antagonista selectivo de nmda del cerebro anterior y un compuesto capaz de aumentar la retroalimentacion excitadora de un nucleo lateral ventral del talamo al cortex para el tratamiento - Google Patents

Producto farmaceutico que comprende una cantidad sinergica de un antagonista selectivo de nmda del cerebro anterior y un compuesto capaz de aumentar la retroalimentacion excitadora de un nucleo lateral ventral del talamo al cortex para el tratamiento

Info

Publication number
CO4700422A1
CO4700422A1 CO96026135A CO96026135A CO4700422A1 CO 4700422 A1 CO4700422 A1 CO 4700422A1 CO 96026135 A CO96026135 A CO 96026135A CO 96026135 A CO96026135 A CO 96026135A CO 4700422 A1 CO4700422 A1 CO 4700422A1
Authority
CO
Colombia
Prior art keywords
increasing
talamo
nucleum
ventral
treatment
Prior art date
Application number
CO96026135A
Other languages
English (en)
Inventor
Bertrand L Chenard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO4700422A1 publication Critical patent/CO4700422A1/es

Links

Classifications

    • G—PHYSICS
    • G10—MUSICAL INSTRUMENTS; ACOUSTICS
    • G10H—ELECTROPHONIC MUSICAL INSTRUMENTS; INSTRUMENTS IN WHICH THE TONES ARE GENERATED BY ELECTROMECHANICAL MEANS OR ELECTRONIC GENERATORS, OR IN WHICH THE TONES ARE SYNTHESISED FROM A DATA STORE
    • G10H5/00—Instruments in which the tones are generated by means of electronic generators
    • G10H5/10—Instruments in which the tones are generated by means of electronic generators using generation of non-sinusoidal basic tones, e.g. saw-tooth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Multimedia (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Esta invención se refiere a un procedimiento para tratar laEnfermedad de Parkinson en el que se trata un mamífero que sufre la Enfermedad de Parkinson con una combinación de un antagonista selectivo de NMDA del cerebro anterior y un compuesto que es capaz de aumentar la retroalimentación excitadora desde el núcleo ventrolateral del tálamo al cortéx. Esta invención también se refiere a composiciones farmacéuticas que contienen la combinación sinérgica.
CO96026135A 1995-05-26 1996-05-23 Producto farmaceutico que comprende una cantidad sinergica de un antagonista selectivo de nmda del cerebro anterior y un compuesto capaz de aumentar la retroalimentacion excitadora de un nucleo lateral ventral del talamo al cortex para el tratamiento CO4700422A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1995/000398 WO1996037226A2 (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective nmda antagonists
HU9601419A HUP9601419A3 (en) 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease

Publications (1)

Publication Number Publication Date
CO4700422A1 true CO4700422A1 (es) 1998-12-29

Family

ID=89994003

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96026135A CO4700422A1 (es) 1995-05-26 1996-05-23 Producto farmaceutico que comprende una cantidad sinergica de un antagonista selectivo de nmda del cerebro anterior y un compuesto capaz de aumentar la retroalimentacion excitadora de un nucleo lateral ventral del talamo al cortex para el tratamiento

Country Status (26)

Country Link
US (1) US6258827B1 (es)
EP (1) EP0828513B1 (es)
JP (1) JPH11505828A (es)
CN (1) CN1159325A (es)
AT (1) ATE258067T1 (es)
AU (1) AU696258B2 (es)
BR (1) BR9602485A (es)
CA (1) CA2219911C (es)
CO (1) CO4700422A1 (es)
CZ (1) CZ283979B6 (es)
DE (1) DE69532482T2 (es)
DK (1) DK0828513T3 (es)
ES (1) ES2211904T3 (es)
FI (1) FI974323A (es)
HU (1) HUP9601419A3 (es)
IL (1) IL118328A (es)
MX (1) MX9709112A (es)
NO (1) NO962130L (es)
NZ (1) NZ286656A (es)
PL (1) PL314413A1 (es)
PT (1) PT828513E (es)
RU (1) RU2176145C2 (es)
SG (1) SG45479A1 (es)
TR (1) TR199600436A2 (es)
TW (1) TW470740B (es)
WO (1) WO1996037226A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
PL340080A1 (en) * 1997-10-24 2001-01-15 Warner Lambert Co Method of treating disease-related or post-drug dyskinesias
WO2001030330A2 (en) 1999-10-29 2001-05-03 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole nmda/nr2b antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
US7217716B2 (en) 2001-02-23 2007-05-15 Merck & Co., Inc. N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
WO2002080928A1 (en) 2001-04-03 2002-10-17 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten
US7148236B2 (en) 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
WO2004032934A1 (en) * 2002-10-08 2004-04-22 Allergan, Inc. Method of using (2-imidazolin-2-ylamino) qinoxalines in the treatment of dementia and parkinsons
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
EP1667630A4 (en) * 2003-09-04 2008-07-23 Univ Texas METHOD AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASES OF GENITAL AND HARVES, INCLUDING PREMATURE WALKING AND LEIOMYOME
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
WO2006042249A2 (en) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methods and compositions for treating migraine pain
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006075004A2 (en) * 2005-01-13 2006-07-20 Neurosearch A/S 3, 8 - substituted 8-aza-bicyclo[3.2.1] octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
US20070118044A1 (en) * 2005-07-18 2007-05-24 Mega Elektroniikka Oy Method and device for identifying; measuring and analyzing abnormal neurological responses
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
RU2324492C1 (ru) * 2006-12-04 2008-05-20 Общество с ограниченной ответственностью "Березовый мир" Средство для профилактики и лечения болезни паркинсона
CN103058957A (zh) 2007-06-29 2013-04-24 埃莫里大学 用于神经保护的nmda受体拮抗剂
NZ590291A (en) * 2008-06-06 2013-11-29 Pharma Two B Ltd Pharmaceutical compositions for treatment of parkinson's disease
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
JP6042968B2 (ja) * 2012-04-20 2016-12-14 ユセベ ファルマ ソシエテ アノニム パーキンソン病の処置方法
MX2016011837A (es) 2014-03-13 2017-04-27 Neuroderm Ltd Composiciones de inhibidores de la dopa decarboxilasa.
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
HU222726B1 (hu) 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
JPH0788355B2 (ja) 1991-04-18 1995-09-27 フアイザー・インコーポレイテツド フェノール性２―ピペリジノ―１―アルカノールのプロドラグエステル
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson

Also Published As

Publication number Publication date
CZ152496A3 (cs) 1998-04-15
WO1996037226A3 (en) 1996-12-27
IL118328A (en) 2001-06-14
AU5451996A (en) 1996-12-05
FI974323A0 (fi) 1997-11-25
NO962130D0 (no) 1996-05-24
WO1996037226A2 (en) 1996-11-28
EP0828513A2 (en) 1998-03-18
RU2176145C2 (ru) 2001-11-27
SG45479A1 (en) 1998-01-16
CA2219911C (en) 2004-07-27
BR9602485A (pt) 1998-04-22
TR199600436A2 (tr) 1996-12-21
CA2219911A1 (en) 1996-11-28
DK0828513T3 (da) 2004-04-13
AU696258B2 (en) 1998-09-03
IL118328A0 (en) 1996-09-12
DE69532482D1 (de) 2004-02-26
MX9709112A (es) 1998-02-28
TW470740B (en) 2002-01-01
CZ283979B6 (cs) 1998-07-15
HU9601419D0 (en) 1996-07-29
HUP9601419A2 (en) 1997-09-29
JPH11505828A (ja) 1999-05-25
ATE258067T1 (de) 2004-02-15
US6258827B1 (en) 2001-07-10
PL314413A1 (en) 1996-12-09
FI974323A (fi) 1997-11-25
NZ286656A (en) 2001-03-30
ES2211904T3 (es) 2004-07-16
NO962130L (no) 1996-11-27
DE69532482T2 (de) 2004-11-25
HUP9601419A3 (en) 1998-01-28
EP0828513B1 (en) 2004-01-21
CN1159325A (zh) 1997-09-17
PT828513E (pt) 2004-05-31

Similar Documents

Publication Publication Date Title
CO4700422A1 (es) Producto farmaceutico que comprende una cantidad sinergica de un antagonista selectivo de nmda del cerebro anterior y un compuesto capaz de aumentar la retroalimentacion excitadora de un nucleo lateral ventral del talamo al cortex para el tratamiento
Lévesque et al. Animal models of temporal lobe epilepsy following systemic chemoconvulsant administration
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
DE60045427D1 (de) Bupropinmetaboliten zur Behandlung von Dementia und anderen zerebrovasckulären Erkrankungen
DE69434211D1 (de) Phenylacetate und derivate, allein oder in kombination mit anderen verbindungen, zur behandlung von neoplastischen und anderen erkrankungen
ATE348829T1 (de) Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
PL347469A1 (en) Use of certain drugs for treating nerve root injury
DE60124972D1 (de) Verwendung von einem Östrogen Agonist/Antagonist zur Behandlung der weiblichen sexuellen Störungen
DE69923998D1 (de) Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
ATE410172T1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
AR003951A1 (es) Formulacion farmaceutica sinergica para el tratamiento de la enfermedad de parkinson y composiciones para prepararla.
Wada et al. The NMDA receptor antagonist MK-801 has a dissociative effect on seizure activity of hippocampal-kindled cats
Rimon et al. Alprazolam and oxazepam in the treatment of anxious out-patients with depressive symptoms: a double-blind multicenter study
HUT59004A (en) Process for applying the interleukine-1 biosynthesis of 3-substituted-2-oxyndole-derivatives carried out as inhibitor
PA8435701A1 (es) Composiciones y metodos farmaceuticos para el tratamiento de una anormalidad en el glutamato y que producen una actividad neuronal en el animal utilizando los inhibidores de la naala